Analysis of time to response to chemotherapy in 316 metastatic breast cancer patients

Oncology. 1993 Nov-Dec;50(6):460-5. doi: 10.1159/000227230.

Abstract

Chemotherapy is a major tool for metastatic breast cancer treatment. In this study, a series of 316 patients have been analyzed to evaluate the time needed to reach tumor response by means of combination chemotherapy. Twenty-five percent of patients responded within 3 months and virtually all responses occurred within 7.5 months. The time curves of response (any) and best response are superimposable. A subset analysis has shown that the following pretreatment characteristics predict a significantly longer time to response: prior exposure to adjuvant chemotherapy, nodal positivity at diagnosis, no previous endocrine treatment and osseous metastases.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology*
  • Chemotherapy, Adjuvant
  • Cyclophosphamide / administration & dosage
  • Cytarabine / administration & dosage
  • Diethylstilbestrol / administration & dosage
  • Epirubicin / administration & dosage
  • Female
  • Humans
  • Lymphatic Metastasis
  • Middle Aged
  • Postmenopause
  • Premenopause
  • Receptors, Estrogen / analysis
  • Receptors, Progesterone / analysis
  • Retrospective Studies
  • Survival Analysis
  • Time Factors

Substances

  • Receptors, Estrogen
  • Receptors, Progesterone
  • Cytarabine
  • Epirubicin
  • Diethylstilbestrol
  • Cyclophosphamide

Supplementary concepts

  • CEF regimen